RC220
Asset
- Stage
- Phase 1
- Modality
- Other
- Target
- Not known
- 1
- Indication
- 0
- Trials
- 1
- Developer
Indications
1Egfr-mutant non-small cell lung cancer
Phase 1, prnewswire.com, 12 Oct 2026
In the full profile
- Owner and partners1
- Signals1
Every asset’s record: target, stage, trials and the evidence behind it.